Health workers may get experimental Ebola vaccine strategy as outbreak grows

What the report says

Bloomberg reported that frontline medical staff in eastern Democratic Republic of Congo may soon be offered an experimental Ebola vaccination approach as an outbreak involving the Bundibugyo strain grows. The proposed study would focus on health workers, who face elevated exposure risks while treating patients, including in areas such as Bunia, where Bloomberg’s article featured health workers carrying an Ebola patient.

According to Bloomberg, researchers are preparing to test whether Merck & Co.’s approved Ebola vaccine, Ervebo, which was developed for the Zaire strain, can be used first, followed by an investigational vaccine aimed at Sudan Ebola. The goal is to see whether the combination can trigger an immune response that might offer some protection against Bundibugyo while a vaccine tailored to that strain is still months away.

The trial could start within two weeks if regulators and ethics reviewers authorize it, Bloomberg said, citing an email Sunday from an Addis Ababa-based agency. The report was published July 20, 2026, and updated July 21.

The development matters because Ebola outbreaks can be especially dangerous for health systems when protective tools are limited or strain-specific vaccines are not immediately available. Based on Bloomberg’s reporting, the proposed regimen remains experimental for Bundibugyo, and any rollout would depend on formal approvals and study design. General background: Ebola virus disease can cause severe illness and has multiple species or strains, meaning vaccines effective against one strain may not necessarily provide the same protection against another.